---
annotation-target: fonc-12-960914.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T07:51:56.177Z","updated":"2022-09-16T07:51:56.177Z","document":{"title":"Atypical presentation of patients with chronic myeloid leukemia in chronic phase&mdash;Case report","link":[{"href":"urn:x-pdf:d342191f774329f19b2f7c09de5a16a1"},{"href":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf"}],"documentFingerprint":"d342191f774329f19b2f7c09de5a16a1"},"uri":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","selector":[{"type":"TextPositionSelector","start":1330,"end":1596},{"type":"TextQuoteSelector","exact":"s, about 5% of them carry rare BCR::ABL1 fusiontranscripts, such as e19a2, e8a2, e13a3, e14a3, e1a3, and e6a2. In particular,the e6a2 fusion transcript has been associated with clinically aggressive diseasefrequently presenting in accelerated or blast crisis phases.","prefix":"14a2 BCR::ABL1 fusion transcript","suffix":" To date, there islimited eviden"}]}]}
>```
>%%
>*%%PREFIX%%14a2 BCR::ABL1 fusion transcript%%HIGHLIGHT%% ==s, about 5% of them carry rare BCR::ABL1 fusiontranscripts, such as e19a2, e8a2, e13a3, e14a3, e1a3, and e6a2. In particular,the e6a2 fusion transcript has been associated with clinically aggressive diseasefrequently presenting in accelerated or blast crisis phases.== %%POSTFIX%%To date, there islimited eviden*
>%%LINK%%[[#^xbrca0uyqb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xbrca0uyqb


>%%
>```annotation-json
>{"created":"2022-09-16T07:52:08.118Z","updated":"2022-09-16T07:52:08.118Z","document":{"title":"Atypical presentation of patients with chronic myeloid leukemia in chronic phase&mdash;Case report","link":[{"href":"urn:x-pdf:d342191f774329f19b2f7c09de5a16a1"},{"href":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf"}],"documentFingerprint":"d342191f774329f19b2f7c09de5a16a1"},"uri":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","selector":[{"type":"TextPositionSelector","start":1958,"end":2116},{"type":"TextQuoteSelector","exact":" Treatment with thesecond-generation tyrosine kinase inhibitor nilotinib was effective in ourpatient expressing the atypical e6a2 BCR::ABL1 fusion transcript.","prefix":"CR::ABL1 e6a2 fusion transcript.","suffix":"KEYWORDSchronic myedoid leukemia"}]}]}
>```
>%%
>*%%PREFIX%%CR::ABL1 e6a2 fusion transcript.%%HIGHLIGHT%% ==Treatment with thesecond-generation tyrosine kinase inhibitor nilotinib was effective in ourpatient expressing the atypical e6a2 BCR::ABL1 fusion transcript.== %%POSTFIX%%KEYWORDSchronic myedoid leukemia*
>%%LINK%%[[#^d5bu2qpk5je|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^d5bu2qpk5je


>%%
>```annotation-json
>{"created":"2022-09-16T07:53:59.620Z","updated":"2022-09-16T07:53:59.620Z","document":{"title":"Atypical presentation of patients with chronic myeloid leukemia in chronic phase&mdash;Case report","link":[{"href":"urn:x-pdf:d342191f774329f19b2f7c09de5a16a1"},{"href":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf"}],"documentFingerprint":"d342191f774329f19b2f7c09de5a16a1"},"uri":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","selector":[{"type":"TextPositionSelector","start":18281,"end":18554},{"type":"TextQuoteSelector","exact":"In fact, the use of conventional multiplex RT-PCR usuallyfails to detect uncommon BCR::ABL1 rearrangements due to thegeneration of atypical PCR products, which are often interpretedas nonspecific and may lead to misdiagnosis, thus excluding thepatient from targeted therapy","prefix":"ogic diseases but suspected CML.","suffix":". While atypical transcripts in "}]}]}
>```
>%%
>*%%PREFIX%%ogic diseases but suspected CML.%%HIGHLIGHT%% ==In fact, the use of conventional multiplex RT-PCR usuallyfails to detect uncommon BCR::ABL1 rearrangements due to thegeneration of atypical PCR products, which are often interpretedas nonspecific and may lead to misdiagnosis, thus excluding thepatient from targeted therapy== %%POSTFIX%%. While atypical transcripts in*
>%%LINK%%[[#^xwt3xvo1o9r|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xwt3xvo1o9r


>%%
>```annotation-json
>{"created":"2022-09-16T07:54:18.725Z","updated":"2022-09-16T07:54:18.725Z","document":{"title":"Atypical presentation of patients with chronic myeloid leukemia in chronic phase&mdash;Case report","link":[{"href":"urn:x-pdf:d342191f774329f19b2f7c09de5a16a1"},{"href":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf"}],"documentFingerprint":"d342191f774329f19b2f7c09de5a16a1"},"uri":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","selector":[{"type":"TextPositionSelector","start":18882,"end":18917},{"type":"TextQuoteSelector","exact":"CML patients with rare transcripts ","prefix":"e and prognosticsignificance of ","suffix":"in a largecohort of 2,331 patien"}]}]}
>```
>%%
>*%%PREFIX%%e and prognosticsignificance of%%HIGHLIGHT%% ==CML patients with rare transcripts== %%POSTFIX%%in a largecohort of 2,331 patien*
>%%LINK%%[[#^8uc2mua7iv4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8uc2mua7iv4


>%%
>```annotation-json
>{"created":"2022-09-16T07:54:37.672Z","updated":"2022-09-16T07:54:37.672Z","document":{"title":"Atypical presentation of patients with chronic myeloid leukemia in chronic phase&mdash;Case report","link":[{"href":"urn:x-pdf:d342191f774329f19b2f7c09de5a16a1"},{"href":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf"}],"documentFingerprint":"d342191f774329f19b2f7c09de5a16a1"},"uri":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/fonc-12-960914.pdf","selector":[{"type":"TextPositionSelector","start":18957,"end":19336},{"type":"TextQuoteSelector","exact":" Rare transcripts were found in 40(1.7%) patients, including e1a2 (0.9%), e19a2 (0.4%), e13a3(0.1%), and e14a3 (0.3%). Compared to patients with thetypical transcript, those with the e1a2 transcript had aninferior response to TKIs [complete cytogenetic response rate(CCyR), 19.0% vs. 79.9%; p < 0.001] and an inferior 3-yearoverall survival (OS) rate (83.9% vs. 98.7%; p < 0.001)","prefix":"gecohort of 2,331 patients (15).","suffix":". Patientswith the e19a2 transcr"}]}]}
>```
>%%
>*%%PREFIX%%gecohort of 2,331 patients (15).%%HIGHLIGHT%% ==Rare transcripts were found in 40(1.7%) patients, including e1a2 (0.9%), e19a2 (0.4%), e13a3(0.1%), and e14a3 (0.3%). Compared to patients with thetypical transcript, those with the e1a2 transcript had aninferior response to TKIs [complete cytogenetic response rate(CCyR), 19.0% vs. 79.9%; p < 0.001] and an inferior 3-yearoverall survival (OS) rate (83.9% vs. 98.7%; p < 0.001)== %%POSTFIX%%. Patientswith the e19a2 transcr*
>%%LINK%%[[#^8acqpcc22i4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8acqpcc22i4
